ArticleCureus2025
Sebaceous Carcinoma as a Presentation of Muir-Torre Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muir-Torre syndrome (MTS) is a rare, autosomal dominant condition that is within the spectrum of Lynch syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)). Sebaceous adenomas are among the most specific manifestations of MTS. Other malignancies include tumors of the colon, rectum, and genitourinary systems, such as endometrial, ovarian, urothelial, and prostate cancer. Individuals at risk for MTS are identified using the Mayo score, which assesses risk based on family history of Lynch syndrome-associated cancers, personal history of these cancers, and age at diagnosis of a sebaceous adenoma or visceral malignancy. We present a case of a firm, red-yellow papule on the upper extremity, which was revealed by a biopsy to be a sebaceous adenocarcinoma. Immunohistochemistry was significant for the loss of MSH2 and MLH1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.